“In Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics (INKT). “Since quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD – we can achieve substantial clinical program advancements.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- Mink Therapeutics, Inc. (INKT) Q2 Earnings Cheat Sheet
- H.C. Wainwright downgrades MiNK Therapeutics after 400% rally
- MiNK Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- MiNK Therapeutics announces publication of article on CAR-iNKT in Frontiers
- MiNK Therapeutics Enters $50M Sales Agreement with B. Riley